DNAJC11

Across TCGA pan-cancer cohorts, DNAJC11 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DNAJC11’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DNAJC11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DNAJC11 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where DNAJC11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DNAJC11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.873	<.001	12	view →
LUAD	Female	II,III,IV	+0.621	<.001	9	view →
LSCC	Female	All	+0.301	<.001	8	view →
HNSC	All	All	−0.168	.005	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DNAJC11–CCRCC

Open the CCRCC breakdown →